France Grapples with Persistent and Worsening Eye Drop Supply Shortages, Prompting Urgent National and International Measures

France is currently facing persistent and escalating supply chain disruptions affecting various ophthalmic solutions, commonly known as eye drops. The National Agency for the Safety of Medicines and Health Products (ANSM) issued a stark warning on Thursday, July 24, 2026, confirming that these shortages have been ongoing for several months and are now significantly exacerbated by production difficulties at a key French manufacturing site, Excelvision. In response, the ANSM has called for an immediate increase in imports and urged healthcare professionals to limit prescriptions to only the strictly necessary quantities, while advising against precautionary stocking by patients and pharmacies alike. This critical situation highlights a broader vulnerability within the pharmaceutical supply chain, impacting patient care and prompting a re-evaluation of national and international drug availability strategies.

Escalating Concerns: The Current Shortage Landscape

The current crisis primarily impacts single-dose eye drop formulations, which are widely prescribed due to their sterility and convenience, particularly for patients with chronic conditions or those requiring precise dosages. The ANSM’s communiqué explicitly stated, "Supply tensions have affected various eye drops for several months for varied reasons. These tensions are now accentuated by difficulties encountered at the French production site of Excelvision." This domestic manufacturing issue comes at a time when the international market for certain ophthalmic medications is already described as "fragile," indicating a global rather than isolated problem. While the agency notes that alternatives or different presentations of some medications may help cover a portion of patient needs, the overall situation remains precarious, posing significant challenges for ophthalmologists, pharmacists, and, most importantly, patients relying on these essential treatments.

Eye drops are a diverse category of medications, ranging from those used for routine examinations to complex treatments for a multitude of ocular conditions. They can be prescribed to dilate pupils for diagnostic purposes, or to treat infections (antibiotics), manage allergies (antiallergics), reduce inflammation (anti-inflammatories), or provide pain relief (anesthetics). The scarcity of these vital medications can disrupt diagnostic procedures, delay crucial treatments, and potentially lead to the worsening of eye conditions, ranging from minor irritations to severe, vision-threatening diseases like glaucoma or serious infections. The potential for long-term health consequences underscores the urgency of the ANSM’s appeal and the need for a coordinated response across the healthcare ecosystem.

A Broader Context: Recurrent Pharmaceutical Supply Chain Challenges

The current eye drop shortage is not an isolated incident but rather a symptom of deeper, systemic vulnerabilities within the global pharmaceutical supply chain that have become increasingly evident over recent years. France, like many other developed nations, has repeatedly faced issues with the availability of essential medicines across various therapeutic areas. Reports from 2024, for instance, indicated a complex picture of medication availability, with some improvements in certain categories but persistent difficulties in others. The causes of these recurrent shortages are multifaceted and complex, often originating from various points along the intricate supply chain.

Key contributing factors include:

• Manufacturing Difficulties: Problems arising during the production of active pharmaceutical ingredients (APIs) or finished products, which can be due to technical glitches, equipment failures, or compliance issues at manufacturing plants.
• Raw Material Shortages: A globalized supply chain means reliance on a limited number of suppliers for critical raw materials, often concentrated in specific regions. Disruptions in these regions (e.g., geopolitical events, natural disasters, public health crises) can have cascading effects worldwide.
• Quality Defects: Batches of medication failing quality control tests can lead to widespread recalls and immediate supply gaps.
• Insufficient Production Capacity: Pharmaceutical companies may struggle to meet sudden surges in demand or maintain adequate stock levels due to limited production lines or underinvestment in manufacturing infrastructure.
• Economic Factors: Pricing pressures, particularly for older, generic drugs, can make production less profitable, leading manufacturers to scale back or cease production of certain medications.
• Logistical Challenges: Transportation disruptions, customs delays, and inventory management issues can also impede the timely delivery of medicines.

The pharmaceutical industry’s "just-in-time" inventory management practices, while efficient in normal times, offer little buffer during unexpected disruptions, exacerbating the impact of any single point of failure. Furthermore, a significant portion of drug manufacturing, especially for APIs, has shifted to countries with lower production costs, creating long and complex supply routes that are more susceptible to disruptions.

Timeline of Disruption and Official Response

The current eye drop supply issues, as acknowledged by the ANSM, have been "since several months," indicating a gradual onset that has progressively worsened. The situation reached a critical point with the recent difficulties at Excelvision, a prominent French production facility, which serves as a significant supplier of ophthalmic products. While specific details of the Excelvision difficulties were not immediately disclosed, such issues often involve unexpected shutdowns for quality control, equipment malfunction, or regulatory compliance reviews.

In response to this escalating crisis, the ANSM has outlined several critical actions:

1. Recourse to Imports: The agency has specifically requested the facilitation of imports of affected eye drops from other countries to supplement domestic supply. This measure aims to quickly bridge the immediate supply gap by leveraging international availability.
2. Limiting Prescriptions: Healthcare professionals, including ophthalmologists and general practitioners, have been instructed to "limit prescriptions and dispensations to strictly necessary quantities." This directive is designed to conserve existing stock and ensure that available medications are prioritized for patients with the most urgent needs.
3. Avoiding Precautionary Stocking: Patients and pharmacists are strongly advised against accumulating "precautionary stocks." While understandable from an individual perspective, widespread hoarding can rapidly deplete existing supplies and worsen the overall shortage for everyone. This mirrors similar appeals made during previous medication shortages, such as those for certain antibiotics or pain relievers.
4. Information Dissemination: The ANSM has committed to keeping healthcare professionals and the public informed through regular updates on the availability of specific products and any alternative treatment recommendations. This transparency is crucial for managing expectations and facilitating appropriate patient care.

These measures reflect a coordinated effort to manage the immediate crisis, but they also underscore the need for more robust, long-term strategies to enhance pharmaceutical supply chain resilience.

Inferred Reactions from Stakeholders

While direct quotes from all parties were not provided in the original dispatch, the implications of such a shortage naturally elicit predictable reactions across the healthcare spectrum:

• Patients: Individuals suffering from chronic eye conditions such as glaucoma, dry eye syndrome, or allergic conjunctivitis are likely experiencing significant anxiety and frustration. The inability to access prescribed medications can lead to discomfort, fear of disease progression, and a decline in quality of life. Patients requiring eye drops for post-surgical care or acute infections face potentially serious complications if treatment is delayed or unavailable. They would likely express concerns about continuity of care and demand clear communication from health authorities.
• Ophthalmologists and Healthcare Professionals: Physicians are placed in a challenging position, having to navigate treatment protocols with limited resources. This may involve exploring less ideal alternative medications, adjusting treatment regimens, or delaying non-urgent procedures. The increased administrative burden of checking stock availability and communicating with patients about shortages can detract from direct patient care. They would likely advocate for immediate solutions and better long-term supply chain planning.
• Pharmacists: As the frontline distributors of medicines, pharmacists bear the brunt of managing patient expectations and sourcing available alternatives. They face the difficult task of explaining shortages to anxious patients, contacting prescribers for alternative options, and meticulously managing their dwindling stock. This situation adds considerable stress and workload to an already demanding profession. Pharmacists would likely call for clearer guidance, more stable supply lines, and better communication from manufacturers and regulators.
• Pharmaceutical Industry (including Excelvision): Manufacturers like Excelvision would likely be working intensely to resolve their production issues, understanding the critical nature of their products. They might issue statements acknowledging the difficulties, outlining remedial actions, and providing timelines for the resumption of normal supply, while also emphasizing the complexities of pharmaceutical manufacturing and the inherent challenges in global supply chains. Other manufacturers might explore opportunities to increase their own production to fill the gap, if feasible.
• Government and Ministry of Health: The French Ministry of Health would likely acknowledge the seriousness of the situation, reiterating their commitment to patient safety and access to essential medicines. They might initiate discussions on national strategies to bolster domestic production, diversify sourcing, and enhance early warning systems for future shortages, potentially collaborating with European partners.

The Economic and Public Health Implications

The persistent shortage of eye drops carries significant economic and public health implications beyond individual patient distress. From a public health perspective, untreated or undertreated eye conditions can lead to increased morbidity, potential vision loss, and a greater burden on emergency healthcare services if conditions escalate. For instance, uncontrolled glaucoma due to lack of medication can lead to irreversible blindness, while untreated eye infections can result in severe damage and even systemic complications. The necessity of dilating eye drops for routine check-ups means that diagnostic procedures could be delayed, potentially missing early signs of serious conditions.

Economically, the need to resort to imports can lead to higher costs for the healthcare system, as imported medications may be more expensive than domestically produced ones. The administrative burden on healthcare professionals and pharmacists translates into lost productivity and increased operational costs. Moreover, patients might incur additional expenses if they need to travel further to find pharmacies with stock or pay for alternative treatments not covered by insurance. The broader impact on public confidence in the healthcare system, particularly regarding the reliability of essential medicine supply, is also a significant, albeit harder to quantify, cost. The earlier cited figure of "up to 1.7 billion euros of unconsumed medicines each year" in France, while not directly related to shortages, highlights inefficiencies in medicine management that, if addressed, could potentially free up resources or improve overall drug utilization.

Towards Greater Pharmaceutical Resilience

The recurring nature of drug shortages, now impacting a critical category like eye drops, underscores the urgent need for comprehensive, long-term strategies to enhance pharmaceutical supply chain resilience both nationally and at a European level. Several pathways could be explored:

• Diversification of Sourcing: Reducing reliance on a single source or a limited number of suppliers for APIs and finished products is crucial. Encouraging multiple manufacturers for essential medicines can create redundancies that absorb shocks.
• Strategic Stockpiling: Governments could consider maintaining national strategic reserves of critical medications to buffer against short-term supply disruptions. This would require careful planning to manage inventory, expiry dates, and storage conditions.
• Investment in Domestic and European Production: Incentivizing the return of pharmaceutical manufacturing to France and other European Union member states can reduce dependence on distant and potentially volatile supply chains. This could involve tax breaks, subsidies, or research and development funding for advanced manufacturing techniques.
• Enhanced Transparency and Data Sharing: Improving real-time data sharing between manufacturers, distributors, and regulatory agencies can provide earlier warnings of impending shortages, allowing for more proactive mitigation strategies.
• Harmonization of Regulatory Processes: Streamlining and harmonizing regulatory approval processes across the EU could facilitate quicker access to alternative medications from member states during a crisis.
• International Cooperation: Strengthening collaboration with international partners on supply chain monitoring, information exchange, and joint procurement initiatives can provide a broader safety net.
• Responsible Prescribing and Dispensing: Continuous education for healthcare professionals on judicious prescribing practices and for patients on responsible medication use can help optimize existing resources and reduce wastage, as indicated by the problem of unconsumed medicines.

The current eye drop shortage in France serves as another critical reminder of the fragility of modern pharmaceutical supply chains. While the immediate focus remains on mitigating the current crisis through imports and controlled distribution, the long-term imperative is to build a more resilient and robust system that can reliably provide essential medications to all who need them, safeguarding public health against future disruptions. The collective experience of recent years, punctuated by crises like the COVID-19 pandemic and numerous drug shortages, must catalyze a fundamental shift towards greater self-sufficiency and strategic preparedness in pharmaceutical supply.